CD274 and non-small cell lung carcinoma: Anti-programmed death ligand-1 (PD-L1) immunotherapy with and without chemotherapy are now the standard of care in multiple cancers, including front-line therapy in advanced-stage non-small cell lung cancer (NSCLC) (1).